Brainstorm Cell Therapeutics Inc.
Jacob A Frenkel (Director) reports BCLI insider transactions
About this filing
Brainstorm Cell Therapeutics Inc. (BCLI) filed Form 4 (insider transaction) with the SEC on Jul 28, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Jacob A Frenkel · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Jul 24, 2026 | A · grantFootnotes F1 | +100,000 | $0.00 | $0.00 | 343,777 | Direct |
Footnotes
- F1 Represents shares of restricted stock units ("RSUs") issued pursuant to a Consulting Agreement dated July 24, 2026 between the Reporting Person and the Issuer (the "Consulting Agreement") and subject to the 2014 Global Share Option Plan. The RSUs shall vest as to (i) 50% of the award on October 24, 2026, and (ii) the remaining 50% of the award on April 24, 2027, provided that the Reporting Person continues to provide services to the Issuer pursuant to the Consulting Agreement through each applicable vesting date.
More BCLI filings
- 10-Q
Filed Nov 16, 2026
- 8-K
Filed Nov 16, 2026
- 10-Q
Filed Aug 14, 2026
- 8-K
Filed Aug 14, 2026
- 8-K
Filed Jul 30, 2026
- 4
Filed Jul 28, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.